At this year’s Swiss Biotech Day in Basel, PharmaKorell was represented by Dr Konrad Dreizler.

In addition to the General Assembly of the Swiss Biotech Association, where Konrad participated and voted on behalf of PharmaKorell, the main focus was on scientific exchange, market discussions and new contacts.

A particularly interesting aspect was the broad landscape of young biotech companies: many are still in the preclinical phase and are preparing the transition into clinical development. This is precisely the stage at which key questions often arise around GMP structures, regulatory requirements, Qualified Persons and the practical organisation of clinical trial processes.

Konrad exchanged many business cards on site, attended several presentations and systematically engaged in discussions with biotech companies, testing laboratories and CMOs. These conversations once again highlighted how important robust partner structures become once projects move from early research into clinical application.

One special programme highlight was the presentation by FoRx Therapeutics, one of our clients. FoRx is working on precision oncology therapies in the field of DNA replication stress and presented current developments and perspectives at Swiss Biotech Day.

The international nature of the event was also clearly evident, including through delegations from various countries. Particularly interesting was the perspective on innovative countries further afield, such as Australia, and the question of which requirements and support structures are relevant there for export, clinical development and approval.

We return from Basel with valuable technical insights, new contacts and a clearer understanding of the current needs of the biotech community.

Many thanks to the Swiss Biotech Association for organising the event, and to all those who contributed to the open and constructive exchange.